Vikas Lifecare Q3 FY26: income ₹97.76 cr, loss ₹29.28 cr

What was announced and why it matters

Vikas Lifecare Limited has disclosed unaudited financial results for Q3 FY26 (quarter ended December 31, 2025) through newspaper advertisements and exchange filings. The disclosures matter because they provide the latest picture of operating scale, costs, and losses for the period. The company said its results were approved by the Board of Directors in a meeting held on April 21, 2026, after review by the Audit Committee. The same set of results also received a statutory auditor limited review. The company’s filings additionally outline compliance steps under SEBI’s disclosure regulations. Alongside the results, investors are tracking corporate actions such as a proposed warrant issue and an authorised capital increase.

Newspaper advertisements and exchange submission

The company published advertisements of its Q3 FY26 unaudited financial results in Financial Express (English) and Jansatta (Hindi) dated April 24 and 25, 2026. These advertisements covered both consolidated and standalone numbers for the quarter ended December 31, 2025. Vikas Lifecare also stated that it submitted copies of the newspaper advertisements to the National Stock Exchange of India Limited and BSE Limited on April 25, 2026. The disclosures were stated to be in compliance with Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The results were digitally signed by Managing Director Sundeep Kumar Dhawan (DIN: 09508137), as per the disclosure.

Q3 FY26 snapshot: income, expenses and net loss

For Q3 FY26 on a consolidated basis, Vikas Lifecare reported total income of ₹97.76 crore and total expenses of ₹116.16 crore. This translated into a loss before tax of ₹33.18 crore and a consolidated net loss of ₹29.28 crore for the quarter. On a standalone basis, total income was ₹96.39 crore, with a standalone net loss of ₹14.72 crore. The basic and diluted EPS for Q3 FY26 was reported at (-0.04) on consolidated basis and (-0.08) on standalone basis. The same disclosure set also presented Q2 FY26 consolidated figures for comparison.

Sequential movement versus Q2 FY26

The Q2 FY26 consolidated total income was reported at ₹142.19 crore, higher than the ₹97.76 crore reported in Q3 FY26. Q2 FY26 consolidated net loss was reported at ₹118.96 crore, compared with a Q3 FY26 consolidated net loss of ₹29.28 crore. While total income fell sequentially, the reported net loss narrowed sharply on a quarter-on-quarter comparison using these disclosed figures. The company’s published performance summary also cited Q3 (Dec 2025) revenue of ₹97.03 crore versus ₹141.33 crore in Q2 (Sep 2025). This aligns directionally with the total income movement shown in the quarter table.

Nine-month performance through December 2025

For the nine months ended December 31, 2025, the company reported total income of ₹465.60 crore on a consolidated basis and ₹459.49 crore on a standalone basis. In a separate revenue comparison shared in the same information set, nine-month revenue through December 2025 was stated at ₹330.74 crore versus ₹344.82 crore in the same period last year. These figures indicate lower revenue on a year-on-year basis for the nine-month period cited. The company’s quarterly disclosures and newspaper advertisements together provide both quarter-level and year-to-date context.

Q1 FY26 data points and the next earnings date

The provided data set also references “Q1 FY25-26” with revenue of ₹97 crore and a net profit of ₹-14 crore, along with QoQ and YoY percentage changes. Separately, it states that the upcoming earnings date for Vikas Lifecare Ltd. is August 14, 2025. The company’s board meeting calendar included an item to consider and approve financial results for the period ended June 30, 2025 on August 14, 2025. These references collectively place the company’s periodic reporting cadence in context. Investors typically track these dates because they drive scheduled disclosures and trading window restrictions.

Key table: Q3 FY26 vs Q2 FY26 (as disclosed)

Corporate actions in focus: warrants and capital increase

Vikas Lifecare has also issued a postal ballot notice seeking shareholder approval for three resolutions. These include an issuance of 61,90,62,500 convertible warrants worth ₹99.05 crore to promoters and public investors, as stated. The notice also seeks alteration of the Articles of Association to enable future capital issuance. In addition, the company has proposed to increase authorised share capital from ₹235 crore to ₹300 crore to accommodate growth requirements. Such actions can change the company’s capital structure and are therefore watched closely by shareholders.

Stock price and other regulatory updates

The data set states Vikas Lifecare share price was ₹1.52 at the market close (as referenced). It also notes a SEBI adjudication order dated December 19, 2025 that “clears Vikas Lifecare” with no adverse findings or penalties, and advised stakeholders to ignore unauthorised claims. Another update referenced an ED visit on November 13, 2025, which was said to have closed without adverse outcome and with no company impact. Separately, the trading window was stated to be closed since October 1, 2025 due to pending unaudited results, with reopening planned 48 hours after disclosure of results. The company also referenced a board agenda on November 14, 2025 that included approval of results and consideration of fundraising, including a rights issue up to ₹100 crore.

Analysis: what the disclosed numbers indicate

The Q3 FY26 disclosures show a clear drop in total income from Q2 FY26 levels, alongside lower expense levels compared with the prior quarter. Even with lower income, the consolidated net loss is materially smaller than the Q2 FY26 net loss as disclosed. The nine-month revenue comparison cited also shows a decline versus the same period last year. Along with operating performance, the proposed warrant issuance and authorised capital increase suggest the company is actively planning its funding options. Investors will likely connect these disclosures with the timing of approvals, trading window rules, and subsequent results announcements.

Conclusion

Vikas Lifecare’s published Q3 FY26 unaudited results show consolidated total income of ₹97.76 crore and a net loss of ₹29.28 crore, with standalone net loss of ₹14.72 crore for the quarter ended December 31, 2025. The company has also highlighted compliance steps through newspaper publication and exchange submission in April 2026. In parallel, shareholder approvals are being sought for warrants, Articles changes, and an authorised capital increase. The next set of scheduled results and board-led disclosures, including those tied to reporting timelines such as August 14, 2025, will remain key checkpoints for investors tracking the company’s financial trajectory and capital actions.